Editor’s Note From December 3 to 6, the Fifth Tianjin International Breast Cancer Conference was grandly held in Tianjin. The meeting was hosted by the Chinese Anti-Cancer Association and organized…

Editor’s Note The 2025 Yat-sen Breast Cancer Conference, held in conjunction with the 2025 CSCO BC Southern Forum, the Second National Conference on the Release of the Chinese Expert Consensus…

The 2025 Yat-sen Breast Cancer Conference, held in conjunction with the 2025 CSCO BC Southern Forum, the Second National Conference on the Release of the Chinese Expert Consensus on the Diagnosis and Treatment of Young Breast Cancer, and the Fourth Yat-sen Breast Nursing Conference, took place in Guangzhou from December 26 to 27, 2025. The meeting focused on standardized breast cancer care, the evolution of cutting-edge treatment strategies, and precision management of young breast cancer patients, systematically presenting the latest advances and future directions in the field. During the conference, Oncology Frontier invited Professor Jing Yao from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, to interpret the newly released Chinese Expert Consensus on the Diagnosis and Treatment of Young Breast Cancer (2025 Edition), and to analyze the characteristics, treatment strategies, and evolving screening approaches for young breast cancer patients in China.

Spotlight on SABCS, insights delivered live. The 48th San Antonio Breast Cancer Symposium (SABCS) was held from December 9 to 12, 2025, in San Antonio, USA, bringing together cutting-edge research findings and clinical insights from across the global breast cancer community. To efficiently convey the highlights of the meeting, this edition of Insight Broadcast invited Professor Junjie Li from Fudan University Shanghai Cancer Center as an on-site expert commentator. Focusing on neoadjuvant therapy for HER2-positive breast cancer, Professor Li provides an in-depth interpretation of the latest research advances on the use of biomarkers such as tumor-infiltrating lymphocytes (TILs) and circulating tumor DNA (ctDNA) to enable more precise patient selection and response prediction, while critically examining their potential, limitations, and future directions from a clinical perspective.

Spotlight on SABCS, insights delivered in real time. The 48th San Antonio Breast Cancer Symposium (SABCS) was held from December 9 to 12, 2025, in San Antonio, USA, bringing together cutting-edge research findings and clinical insights from the global breast cancer community. To efficiently convey the key messages of the meeting, this edition of Insight Broadcast invited Professor Jin Yang from the First Affiliated Hospital of Xi’an Jiaotong University as the on-site expert commentator. Drawing on two pivotal studies—ASCENT-07 and lidERA—Professor Yang interprets the latest advances and challenges in first-line treatment of advanced disease and adjuvant therapy in early-stage HR+/HER2− breast cancer, while exploring the evolving treatment paradigm and future directions.

At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), results were presented from a study titled “HER2CLIMB-05: A Randomized, Double-Blind Phase III Study of Tucatinib versus Placebo in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy for HER2-Positive Metastatic Breast Cancer” (Abstract No. GS1-01). This study explored an intensified strategy for first-line maintenance therapy in patients with HER2-positive metastatic breast cancer (HER2+ MBC). Oncology Frontier invited Professor Xiaoyun Mao from The First Hospital of China Medical University to provide a detailed overview and expert commentary on the study, with the aim of optimizing clinical decision-making.

Recently, the 17th Shanghai Breast Cancer Professional Symposium, held in conjunction with the Annual Meeting of the Breast Cancer Committee of the Shanghai Anti-Cancer Association and the 2026 Breast Cancer Guideline “Red Book” Update Meeting, took place in Shanghai. During the meeting, the 2026 Edition of the Essentials of the Breast Cancer Diagnosis and Treatment Guidelines and Specifications—jointly issued by the Chinese Anti-Cancer Association Breast Cancer Committee (CBCS) and the Breast Oncology Group of the Chinese Society of Clinical Oncology (CSOBO)—was officially released (hereinafter referred to as the new Red Book).

Editor’s Note The 17th Shanghai Breast Cancer Professional Symposium, held in conjunction with the Annual Meeting of the Breast Cancer Committee of the Shanghai Anti-Cancer Association and the 2026 Breast…